397 related articles for article (PubMed ID: 33218331)
1. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy.
Kagami T; Yamade M; Suzuki T; Uotani T; Tani S; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Baba S; Sugimura H; Murai J; Pommier Y; Furuta T
BMC Cancer; 2020 Nov; 20(1):1123. PubMed ID: 33218331
[TBL] [Abstract][Full Text] [Related]
2. High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
Zhou XL; Wang WW; Zhu WG; Yu CH; Tao GZ; Wu QQ; Song YQ; Pan P; Tong YS
Mol Carcinog; 2016 Dec; 55(12):2095-2105. PubMed ID: 26756568
[TBL] [Abstract][Full Text] [Related]
3. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
Yap WK; Chang YC; Hsieh CH; Chao YK; Chen CC; Shih MC; Hung TM
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):689-698. PubMed ID: 29188300
[TBL] [Abstract][Full Text] [Related]
4. Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy.
Okamoto H; Fujishima F; Kamei T; Nakamura Y; Ozawa Y; Miyata G; Nakano T; Katsura K; Abe S; Taniyama Y; Sakurai T; Teshima J; Hikage M; Sasano H; Ohuchi N
BMC Cancer; 2015 Mar; 15():208. PubMed ID: 25880782
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.
Sugawara K; Yagi K; Okumura Y; Nishida M; Aikou S; Yamashita H; Yamashita H; Seto Y
Int J Clin Oncol; 2020 Apr; 25(4):552-560. PubMed ID: 31828451
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study.
Kawakami T; Tsushima T; Omae K; Ogawa H; Shirasu H; Kito Y; Yoshida Y; Hamauchi S; Todaka A; Machida N; Yokota T; Yamazaki K; Fukutomi A; Onozawa Y; Yasui H
BMC Cancer; 2018 May; 18(1):573. PubMed ID: 29776344
[TBL] [Abstract][Full Text] [Related]
7. Effect of consolidation chemotherapy following definitive chemoradiotherapy in patients with esophageal squamous cell cancer.
Wu SX; Li XY; Xu HY; Xu QN; Luo HS; Du ZS; Huang HC; Wu ZY
Sci Rep; 2017 Dec; 7(1):16870. PubMed ID: 29203855
[TBL] [Abstract][Full Text] [Related]
8. YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
Dai H; Shao YW; Tong X; Wu X; Pang J; Feng A; Yang Z
Cancer Med; 2020 Mar; 9(5):1628-1637. PubMed ID: 31851786
[TBL] [Abstract][Full Text] [Related]
9. Endoscopic findings suggestive of a high risk of non-radical cure after definitive chemoradiotherapy for cT1bN0M0 esophageal squamous cell carcinoma.
Fukuhara M; Urabe Y; Oka S; Ishibashi K; Konishi H; Mizuno J; Tanaka H; Tsuboi A; Yamashita K; Hiyama Y; Takigawa H; Kotachi T; Yuge R; Hayashi R; Nishibuchi I; Murakami Y; Nagata Y; Tanaka S
Esophagus; 2023 Jul; 20(3):541-547. PubMed ID: 37027046
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiotherapy With or Without Surgery for Esophageal Squamous Cancer According to Hospital Volume.
Duarte MBO; Pereira EB; Lopes LR; Andreollo NA; Carvalheira JBC
JCO Glob Oncol; 2020 Jun; 6():828-836. PubMed ID: 32552112
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
[TBL] [Abstract][Full Text] [Related]
12. Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy.
Hamada S; Kano S; Murai J; Suzuki T; Tsushima N; Mizumachi T; Suzuki M; Takashima T; Taniyama D; Sakamoto N; Fujioka Y; Ohba Y; Homma A
Front Oncol; 2022; 12():978875. PubMed ID: 36741698
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
14. Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma.
Jeong H; Im HS; Bang Y; Kim YH; Kim HR; Lee HJ; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Lee JH; Ahn JY; Na HK; Ryu JS; Kang J; Kim SB; Kim JH; Park SR
Cancer Med; 2021 Mar; 10(5):1745-1758. PubMed ID: 33590710
[TBL] [Abstract][Full Text] [Related]
15. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
[TBL] [Abstract][Full Text] [Related]
16. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy.
Matsuda S; Tsubosa Y; Niihara M; Sato H; Takebayashi K; Kawamorita K; Mori K; Tsushima T; Yokota T; Ogawa H; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Ann Surg Oncol; 2015; 22(6):1866-73. PubMed ID: 25564176
[TBL] [Abstract][Full Text] [Related]
17. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
Conteduca V; Ku SY; Puca L; Slade M; Fernandez L; Hess J; Bareja R; Vlachostergios PJ; Sigouros M; Mosquera JM; Sboner A; Nanus DM; Elemento O; Dittamore R; Tagawa ST; Beltran H
Mol Cancer Ther; 2020 May; 19(5):1157-1164. PubMed ID: 32127465
[TBL] [Abstract][Full Text] [Related]
18. Value of blood oxygenation level-dependent magnetic resonance imaging in early evaluation of the response and prognosis of esophageal squamous cell carcinoma treated with definitive chemoradiotherapy: a preliminary study.
Zheng H; Zhang H; Zhu Y; Wei X; Liu S; Ren W
BMC Med Imaging; 2024 Jan; 24(1):18. PubMed ID: 38216885
[TBL] [Abstract][Full Text] [Related]
19. FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy.
Iwabu J; Yamashita S; Takeshima H; Kishino T; Takahashi T; Oda I; Koyanagi K; Igaki H; Tachimori Y; Daiko H; Nakazato H; Nishiyama K; Lee YC; Hanazaki K; Ushijima T
Sci Rep; 2019 Sep; 9(1):13347. PubMed ID: 31527639
[TBL] [Abstract][Full Text] [Related]
20. The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma.
Ma MW; Gao XS; Gu XB; Xie M; Cui M; Zhang M; Liu L; Yin H; Chen LQ
World J Surg Oncol; 2018 Aug; 16(1):172. PubMed ID: 30119684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
